A randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetics, pharmacodynamics trial of multiple ascending fixed doses of SRA-333 [lecozotan] in subjects with mild to moderate Alzheimer's disease.
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Lecozotan (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 10 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2005 New trial record.